NIH’s Dr. Carl Dieffenbach Shares Highlights from Start of CROI 2016 (Video)

Content From: Miguel Gomez, Director,, and Senior Communications Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human ServicesPublished: February 24, 20161 min read


After the first full day of sessions at the 2016 Conference on Retroviruses andOpportunistic Infections (CROI)Exit Disclaimer in Boston yesterday, February 23, we caught up with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), to get his take on some of the key highlights of the day.

In this brief video he highlights two important presentations about improvements in antiretroviral therapy (ART) and the next generation of both HIV treatment and HIV prevention. These included discussions about therapies that maintain their effectiveness over long periods of time that could be delivered as a monthly injection instead of as a daily pill. Dr. Dieffenbach highlighted, specifically, a plenary session by Dr. Joe Eron of UNC Chapel Hill titled “Antiretroviral Therapy: Where Are We Now? Where Are We Going?Exit Disclaimer and another session by Dr. Ian McGowan of the University of Pittsburgh School of Medicine titled “The Promise and Challenges of Sustained Delivery of PrEPExit Disclaimer.

The annual CROI conference has assembled nearly 4,000 basic, translational, and clinical researchers from 96 countries to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.

Tomorrow Dr. Dieffenbach will return to share brief highlights of the science presented on Wednesday, February 24.